Skip to content
value.today

BioPharmX Corp

🇺🇸 Menlo Park, California, USAPharmaceuticalsFounded 2010
Total raised
$8 M
1 round on record
Latest round
$8 M
Apr 2014
First round on record
Apr 2014
Today
Private
No later event on record

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of BioPharmX Corp
MonthRaisedRaiseSizeInvestorsSoldFiling
Apr 2014$8 MNo. 1$2 to $10 million

BioPharmX Corp: Raise no. 1, Apr 2014

Investors in this round

51 investors had bought by the notice of Mar 19, 2015: 51 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for BioPharmX Corp as a whole in other filings: see Investors below.

What the notice says

Amount sold
$8 M of $19 M offered; $11 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
$227,228
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Anja Krammer · Executive Officer, Director · President
  • James Pekarsky · Executive Officer, Director · CEO and CFO
  • Kin Chan · Executive Officer · Executive Vice President of R&D
  • Michael Hubbard · Director
  • Ping Wang · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On fees: “Finders Fees were paid in shares of Series A Preferred Stock at the value of $1.85 per share and are included in the amount listed in Item 13 under Total Amount Sold.”
  • On the amounts: “Amount sold includes the sale of Series A Stock. Total remaining to be sold includes warrant shares that may be purchased by the respective holders multiplied by the exercise price. Issuer will not receive any cash proceeds unless warrants are exercised.”

Signed by James Pekarsky, CEO and CFO. Source: SEC Form D and 1 amendment, newest notice filed Mar 19, 2015. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • BioPharmX Corp chose not to state its revenue in its newest notice of a funding round (Mar 2015).

    SEC Form D · Mar 2015

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Mar 2015

That is all the official record says: BioPharmX Corp has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

3 named in official filings. Open an investor to see everything it has backed.

Investors in BioPharmX Corp
InvestorKindAmountRoundRoleSource
Ping WangPersonnot statednot statedHeld Series A preferred stock, director (Form 3, 2015)SEC Form 3
Stephen MorlockPersonnot statednot statedHeld Series A preferred stock, director (Form 3, 2015)SEC Form 3
Vivo Capital VIII, LLCFund or asset managernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2016)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 51 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by BioPharmX Corp
NameRoleNamed in
Anja KrammerPresidentMar 2015
James PekarskyCEO and CFOMar 2015
Kin ChanExecutive Vice President of R&DMar 2015
Anja KrammerPresidentMar 2015
James PekarskyCEO and CFOMar 2015
Michael HubbardDirectorMar 2015
Ping WangDirectorMar 2015